IPO - ATAI Life Sciences N.V.
Form Type: 424B5
Filing Date: 2025-02-13
Corporate Action: Ipo
Type: New
Accession Number: 000114036125004338
Filing Summary: ATAI Life Sciences N.V. is offering 26,190,477 common shares at a price of $2.10 per share. The offering is part of a shelf registration process with the last reported share price at $2.55 as of February 12, 2025. The total proceeds before expenses are estimated to be $51,975,001.60, with underwriting discounts of approximately $3,025,000. The shares are set to be delivered on or about February 14, 2025. The document highlights the company’s focus on developing innovative therapies for significant unmet needs in mental health disorders, which affect over one billion people globally. It has made strategic investments in companies like Beckley Psytech, demonstrating its commitment to advancing research in mental health treatments, including recent Phase II studies showing promising results for its investigational therapies. The company is classified as an emerging growth company, which subjects it to reduced reporting requirements.
Document Link: View Document
Additional details:
Underwriting Discounts And Commissions: $3,025,000
Offering Price Per Share: $2.10
Total Offering Price: $55,000,001.70
Proceeds Before Expenses: $51,975,001.60
Last Reported Sale Price: $2.55
Date Of Prospectus Supplement: 2025-02-12
Expected Delivery Date: 2025-02-14
Form Type: 8-K
Filing Date: 2025-02-13
Corporate Action: Ipo
Type: New
Accession Number: 000114036125004342
Filing Summary: On February 12, 2025, ATAI Life Sciences N.V. entered into an underwriting agreement with Berenberg Capital Markets LLC for the public offering of 26,190,477 common shares at a price of $2.10 per share. The agreement includes an option for the underwriter to purchase an additional 3,928,571 shares within 30 days. The offering is expected to close around February 14, 2025, pending customary conditions. The net proceeds from this offering are estimated to be approximately $51.4 million, or $59.2 million if the underwriter's option is fully exercised, aimed at funding general corporate needs and advancing clinical development. The document also states that the company has sufficient financial resources to cover operating expenses into 2027. An opinion regarding the validity of the common shares was issued by NautaDutilh N.V.
Document Link: View Document
Additional details:
Underwriting Agreement Date: 2025-02-12
Public Offering Price: 2.10
Total Common Shares Offered: 26190477
Additional Shares Option: 3928571
Net Proceeds Estimate: 51.4 million
Full Option Net Proceeds Estimate: 59.2 million
Intended Use Of Proceeds: general corporate purposes, including working capital and clinical development
Anticipated Closing Date: 2025-02-14
Comments
No comments yet. Be the first to comment!